Skip to main content

Table 3 IPTW-weighted model estimated expenditures of 1-year costs after confirmed diagnosis and related cost differences with 95% confidence intervals

From: Comparing outcomes of ILD patients managed in specialised versus non-specialised centres

 

Non-specialised centre

Specialised ILD centre

Difference (in €)

Costs in € (95% CI)

Costs in € (95% CI)

Overall

Totala

13,953 (13,554; 14,353)

13,082 (12,252; 13,906)

− 872 (− 75; 1817)

 Inpatientb

8814 (8482; 9164)

6970 (6364; 7606)

− 1845 (− 2609; − 1133)*

 Outpatienta

1378 (1349; 1406)

1363 (1266; 1453)

− 15 (− 117; 76)

 Pharmaceuticalsa

3761 (3590; 3927)

4753 (4287; 5243)

992 (488; 1562)*

Respiratory-related

Totalb

3717 (3546; 3897)

4385 (3966; 4855)

669 (219; 1156)*

 Inpatientb

2206 (2076; 2352)

1762 (1543; 1993)

− 444 (− 709; − 175)*

 Outpatientb

482 (467; 496)

498 (452; 552)

17 (− 32; 70)

 Pharmaceuticalsb

1029 (936; 1130)

2121 (1754; 2497)

1092 (759; 1464)*

  1. Estimation based on weighted one- and two-part generalized linear gamma models via recycled predictions approach with 1000 bootstrap replicates
  2. CI: Confidence interval, ILD: Interstitial lung disease, IPTW: Inverse probability of treatment weighting
  3. *Statistically significant results
  4. aOne-part model
  5. bTwo-part model